|
HRP20150074T1
(hr)
*
|
2007-10-01 |
2015-03-13 |
Bristol-Myers Squibb Company |
Humana antitijela koja se vežu za mezotelin i njihove uporabe
|
|
KR101559599B1
(ko)
*
|
2007-11-26 |
2015-10-12 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
항-메소텔린 항체 및 이의 용도
|
|
AR076284A1
(es)
*
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
AU2011349443B2
(en)
*
|
2010-12-20 |
2015-12-24 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
WO2012123755A1
(en)
|
2011-03-17 |
2012-09-20 |
The University Of Birmingham |
Re-directed immunotherapy
|
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
|
SG194567A1
(en)
|
2011-04-21 |
2013-12-30 |
Seattle Genetics Inc |
Novel binder-drug conjugates (adcs) and their use
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
US9416190B2
(en)
*
|
2012-09-27 |
2016-08-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
|
CN103819559B
(zh)
*
|
2013-12-10 |
2016-02-24 |
中国科学院武汉病毒研究所 |
一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途
|
|
AU2014372833B2
(en)
|
2013-12-23 |
2019-08-22 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
|
|
CA2960925A1
(en)
*
|
2014-09-30 |
2016-04-07 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (dprs) antibody
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
EP3770168A1
(en)
|
2015-05-18 |
2021-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
SG11201710639YA
(en)
|
2015-06-22 |
2018-01-30 |
Bayer Pharma AG |
Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
|
|
BR112017027702A2
(pt)
*
|
2015-06-30 |
2018-08-28 |
Henlius Biotech Co Ltd |
anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)
|
|
CN106467573B
(zh)
|
2015-08-21 |
2021-05-25 |
佧珐药业有限公司 |
抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
|
|
KR101782487B1
(ko)
|
2015-09-24 |
2017-09-27 |
재단법인 목암생명과학연구소 |
신규 항-메소텔린 항체 및 이를 포함하는 조성물
|
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
KR20180099768A
(ko)
|
2015-12-30 |
2018-09-05 |
노파르티스 아게 |
증진된 효능을 갖는 면역 이펙터 세포 요법
|
|
EP3418304B1
(en)
*
|
2016-02-15 |
2021-08-04 |
Kanagawa Prefectural Hospital Organization |
Recognition of membrane type mucin-like protein and clinical application thereof
|
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
SG10202008909VA
(en)
|
2016-03-24 |
2020-10-29 |
Bayer Pharma AG |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
US20230071283A1
(en)
|
2016-04-15 |
2023-03-09 |
Aimee S. Payne |
Compositions and methods for selective protein expression
|
|
KR20190014525A
(ko)
|
2016-05-27 |
2019-02-12 |
애브비 바이오테라퓨틱스 인크. |
면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
|
|
WO2017216028A1
(en)
|
2016-06-15 |
2017-12-21 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
SG11201900885VA
(en)
|
2016-08-01 |
2019-02-27 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US20190218294A1
(en)
|
2016-09-09 |
2019-07-18 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
|
CN110177803A
(zh)
|
2016-11-22 |
2019-08-27 |
T细胞受体治疗公司 |
用于使用融合蛋白进行tcr重新编程的组合物和方法
|
|
RS67792B1
(sr)
|
2016-12-01 |
2026-03-31 |
Regeneron Pharma |
Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
|
|
US12059472B2
(en)
|
2016-12-21 |
2024-08-13 |
Bayer Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
US11433140B2
(en)
|
2016-12-21 |
2022-09-06 |
Bayer Pharma Aktiengesellschaft |
Specific antibody drug conjugates (ADCs) having KSP inhibitors
|
|
AU2017380871C1
(en)
|
2016-12-21 |
2025-05-15 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (ADCs) having enzymatically cleavable groups
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
WO2018232020A1
(en)
|
2017-06-13 |
2018-12-20 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
JP6339283B1
(ja)
|
2017-10-31 |
2018-06-06 |
国立大学法人 岡山大学 |
Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体
|
|
WO2019105835A1
(en)
|
2017-11-29 |
2019-06-06 |
Bayer Consumer Care Ag |
Combinations of copanlisib and anetumab ravtansine
|
|
CA3086098A1
(en)
|
2017-12-19 |
2019-06-27 |
F-Star Beta Limited |
Fc binding fragments comprising a pd-l1 antigen-binding site
|
|
MX428412B
(es)
*
|
2017-12-24 |
2025-11-13 |
Noile Immune Biotech Inc |
Celula inmunocompetente que expresa una molecula de superficie celular que reconoce especificamente la mesotelina humana, il-7 y ccl19
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
BR112020021855A2
(pt)
|
2018-04-27 |
2021-02-23 |
Biogen Ma Inc. |
anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
BR112021000394A2
(pt)
|
2018-07-12 |
2021-04-06 |
F-Star Beta Limited |
Moléculas de anticorpo que se ligam a pd-l1 e cd137
|
|
AU2019301206B2
(en)
|
2018-07-12 |
2025-10-30 |
Invox Pharma Limited |
Antibody molecules that bind CD137 and OX40
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
CN109053882B
(zh)
*
|
2018-08-28 |
2019-08-23 |
东莞市朋志生物科技有限公司 |
一种ns1蛋白的结合蛋白以及应用
|
|
SG11202101811VA
(en)
|
2018-08-30 |
2021-03-30 |
Tcr2 Therapeutics Inc |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
JP7728701B2
(ja)
|
2018-12-17 |
2025-08-25 |
レビトープ リミテッド |
双子型免疫細胞エンゲージャー
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20220135658A1
(en)
*
|
2019-03-14 |
2022-05-05 |
Morphosys Ag |
Antibodies targeting c5ar
|
|
CA3133155A1
(en)
|
2019-03-19 |
2020-09-24 |
Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron |
Combination therapy for the treatment for cancer
|
|
WO2020234114A1
(en)
|
2019-05-21 |
2020-11-26 |
Bayer Aktiengesellschaft |
A novel stable high concentration formulation for anetumab ravtansine
|
|
WO2021021825A1
(en)
*
|
2019-07-29 |
2021-02-04 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for inducing notch signaling in tumor microenvironments
|
|
WO2021081232A1
(en)
|
2019-10-23 |
2021-04-29 |
Cue Biopharma, Inc. |
Modified cytotoxic t cells and methods of use thereof
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
IL293640A
(en)
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
|
EP4121454A1
(en)
*
|
2020-03-19 |
2023-01-25 |
Imperial College Innovations Limited |
Coronavirus antibody
|
|
US20230332104A1
(en)
|
2020-06-11 |
2023-10-19 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CN116063527B
(zh)
*
|
2021-09-30 |
2026-05-26 |
南京北恒生物科技有限公司 |
靶向间皮素的抗体及其用途
|
|
TW202321296A
(zh)
|
2021-10-06 |
2023-06-01 |
美商鏈接免疫療法公司 |
抗間皮素抗原結合分子及其用途
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
|
WO2024089013A1
(en)
|
2022-10-25 |
2024-05-02 |
Peptomyc, S.L. |
Combination therapy for the treatment of cancer
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
CN116019939A
(zh)
*
|
2022-11-24 |
2023-04-28 |
华中科技大学同济医学院附属协和医院 |
靶向msln的分子探针以及用途
|
|
EP4626930A2
(en)
*
|
2022-12-02 |
2025-10-08 |
Jecho Laboratories, Inc. |
Anti-mesothelin bispecific antibodies and methods of use
|
|
EP4701654A2
(en)
|
2023-04-25 |
2026-03-04 |
Arsenal Biosciences, Inc. |
Novel receptors for transcription regulation
|
|
WO2024243441A1
(en)
|
2023-05-24 |
2024-11-28 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
EP4724100A1
(en)
|
2023-06-07 |
2026-04-15 |
Fundació Privada Institut d'Investigació Oncològica de Vall Hebron |
Combination therapy with mek inhibitors for the treatment of cancer
|
|
IL325025A
(en)
|
2023-06-07 |
2026-01-01 |
Fundaci? Privada Inst Dinvestigaci? Oncol?Gica De Vall Hebron |
Combination therapy with BRAF inhibitors for cancer treatment
|
|
EP4473974A1
(en)
|
2023-06-07 |
2024-12-11 |
Peptomyc, S.L. |
Omomyc and kras inhibitors combination therapy for the treatment of cancer
|
|
CN117659133B
(zh)
*
|
2023-12-06 |
2024-09-20 |
南京鼓楼医院 |
间皮素靶向结合蛋白、其编码核酸以及用途
|
|
CN117843793B
(zh)
*
|
2024-03-07 |
2024-07-09 |
深圳真实生物医药科技有限公司 |
抗间皮素抗体、抗原结合片段及其用途
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|
|
WO2026037400A1
(en)
*
|
2024-08-16 |
2026-02-19 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Anti-msln antibodies and uses thereof
|
|
US20260109780A1
(en)
|
2024-10-21 |
2026-04-23 |
Sonnet BioTherapeutics, Inc. |
Docking peptides and related antibody-based drug conjugates
|
|
WO2026152120A2
(en)
|
2025-01-13 |
2026-07-16 |
HCW Biologics, Inc. |
Chimeric polypeptides and uses thereof
|